Herbal blend STW 5-II could soothe stomach pain without drugs
NCT ID NCT07198243
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a herbal medicine called STW 5-II can reduce inflammation in the gut lining and ease symptoms like stomach pain, bloating, and fullness after eating in people with functional dyspepsia. About 100 adults will take either the herbal remedy or a placebo for 8 weeks, with tissue samples and symptom diaries used to measure effects. An optional 4-week treatment extension is available for all participants.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- STW 5-II (a blend of six herbal extracts: bitter candy tuft, chamomile, caraway, melissa, peppermint, and licorice root)
- What this could lead to
- If successful, this could point toward a natural, well-tolerated option for managing functional dyspepsia symptoms and reducing gut inflammation.
- What could go wrong
- This is a small, early proof-of-concept trial. The herbal mixture may not outperform placebo, and results may not apply to all patients. Side effects are possible but typically mild.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion Criteria: Inclusion criteria: * Patients ≥18 years newly to be treated with an FD/PDS diagnosis (Rome IV clinical criteria). * Newly to be treated patients are defined as patients currently not on any ongoing treatment for FD (including OTC medication) for the last 2 weeks. Medications such as PPI or others that may affect GI function and symptom should be stopped prior the trial (min 4 weeks). See list of forbidden medication. * Male or female using contraception or postmenopausal * Witnessed written informed consent * Capable to understand and comply with the study requirements Exclusion criteria: * Major active somatic or psychiatric condition that may explain dyspeptic symptoms (stable dose of single antidepressant allowed for psychiatric indication, no limitation for other indications) Predominant symptoms of gastro-esophageal reflux disease (GERD) or irritable bowel syndrome (IBS) * Chronic ppi use. No PPI use for at least the prior 4 weeks before entering the trial- History of major abdominal surgery (except for appendectomy, cholecystectomy or splenectomy) * History or presence of diabetes mellitus type 1 \& type 2, coeliac disease or inflammatory bowel disease * Active malignancy * Known HIV, HBV or HCV infection * Significant alcohol use (\>10 units/weeks) * Females pregnant or lactating * Hypersensitivity against ingredients of STW 5-II or placebo (see annex) * Abnormal baseline laboratory blood values
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Functional dyspepsia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospitals Leuven / UZLeuven
Leuven, 3000, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a nickel allergy explain your Child's stomach pain?
- Can a pudding snack reveal how the brain misreads the stomach?
- Beyond h. pylori: a hidden stomach bacteria may influence cancer risk
- Wheat sensitivity linked to fatty liver? a new study investigates
- Ancient herbal mix targets dual gut disorders in one shot
- Digestive health mystery: study seeks to uncover hidden burden of stomach pain in rural bangladesh